Immunohistochemical (IHC) analyses, as performed previously4, on clinical samples also revealed a significant increase in A3B nuclear protein levels in EGFR TKI-treated tumor samples both at RD and PD timepoints (Fig. 7c,d and Supplementary Table 2c). This evidence concerns the gene APOBEC3B and neoplasm.